Compare Cassava Sciences Inc (FLNA) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs McKesson Corporation — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while McKesson Corporation trades at $839.06 (market cap $93.23B). The key difference: McKesson Corporation is far larger — about 1754.4× Cassava Sciences Inc's market cap, and McKesson Corporation pays a 0.41% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MCK | |
|---|---|---|
Market Cap | $53.14M | $93.23B |
Sector | Health | Health |
52-Week High | $4.64 | $995.69 |
52-Week Low | $1.09 | $659.01 |
Enterprise Value | -$33.43M | $97.87B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
MCK trades at $836.49, up 4.12% in the last session, with a neutral technical signal and strong analyst consensus. Recent earnings consistently beat expectations, with Q1 2026 EPS of $11.69 surpassing the $11.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins remain thin at 1.18%. The stock is supported by positive cash flow trends and a dividend payout scheduled for July 2026.
The outlook is positive, driven by earnings momentum and a $932.83 consensus price target implying 11.5% upside. Risks include low profitability margins and high liabilities, but institutional sentiment is bullish with 80% buy ratings. Investors should weigh growth in specialty pharma against execution and regulatory pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
